Is Lurbinectedin Approved for Infants?
No, lurbinectedin (brand name Zepzelca) is not approved for use in infants or any pediatric patients. The FDA approved it in 2020 solely for adults with metastatic small cell lung cancer (SCLC) who progressed after platinum-based chemotherapy.[1] Labeling specifies adults aged 18 and older, with no pediatric indications.
What Does Clinical Data Show for Kids?
No clinical trials support lurbinectedin use in infants or children. Pediatric studies are absent from its development data, and safety/efficacy in patients under 18 remain unestablished. Dosing, pharmacokinetics, and organ maturity in infants differ sharply from adults, making extrapolation risky.[1][2]
Why Not Safe for Infants?
Infants lack mature liver and kidney function to metabolize lurbinectedin, a CYP3A4 substrate prone to toxicity like severe myelosuppression, fatigue, and nausea in adults. Off-label use could cause life-threatening bone marrow failure or infections, with no dosing guidelines available.[1] Oncologists avoid it in pediatrics due to these gaps.
Alternatives for Pediatric SCLC or Similar Cancers?
Rare pediatric SCLC cases rely on topotecan, irinotecan, or temozolomide, per COG protocols—not lurbinectedin. For infants with other neuroendocrine tumors, options include cyclophosphamide/vincristine or clinical trials via NCTN.[3] Consult pediatric oncologists for age-specific regimens.
Ongoing Pediatric Research or Patents?
No active pediatric trials for lurbinectedin appear on ClinicalTrials.gov. Patents cover adult SCLC formulations through 2034, but none extend to pediatric uses.[4] Jazz Pharmaceuticals holds exclusivity until at least 2025, blocking generics regardless.
[1] FDA Zepzelca Prescribing Information: https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/213069s000lbl.pdf
[2] EMA Lurbinectedin Summary: https://www.ema.europa.eu/en/documents/product-information/zepzelca-epar-product-informationen.pdf
[3] COG Pediatric SCLC Guidelines: https://www.childrensoncologygroup.org
[4] DrugPatentWatch.com Lurbinectedin Patents: https://www.drugpatentwatch.com/p/tradename/ZEPZELCA